Neurogen and Merck Agreement for Next-Generation Pain Drugs Consummated
16-Jan-2004
With consummation of the deal, Neurogen has received $30 million from Merck, including a $15 million up-front license fee payment and a $15 million equity investment in Neurogen common stock. Under the agreement, Merck has purchased shares of newly issued Neurogen common stock.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.